595 results on '"Crohn's disease -- Drug therapy"'
Search Results
2. Pyzchiva, a Biosimilar to Stelara, Gets FDA Approval
3. April 2024: Notable Drug Approvals
4. Biosimilar Cyltezo Now Available in High-Concentration Formulation
5. FDA: Risk of Intrahepatic Cholestasis of Pregnancy With Thiopurines
6. U.S. FDA OKs Subcutaneous Administration of Takedas ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohns Disease
7. Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease
8. Top-Down Treatment Superior for Crohn Disease
9. FDA Approves Simlandi, a Citrate-Free, High-Concentration, Interchangeable Biosimilar to Humira
10. Study Data from University of Genoa Update Knowledge of Crohn's Disease (P603 Comparison of the safety and efficacy of ustekinumab and vedolizumab in patients with Crohn's disease. - A systematic review and meta-analysis of propensity score ...)
11. Researcher from University Hospitals Birmingham Reports on Findings in Crohn's Disease (P548 Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn's Disease - results from a tertiary IBD centre)
12. Research on Crohn's Disease Discussed by a Researcher at University Hospital La Paz (Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease)
13. Research from Ankara University School of Medicine Provides New Study Findings on Crohn's Disease (P618 Comparison of vedolizumab and ustekinumab treatment persistence in anti-TNF experienced Crohn's Disease patients)
14. Reports Outline Crohn's Disease Research from Amsterdam University Medical Center (P767 Pharmacokinetics of subcutaneous infliximab induction and maintenance in patients with moderate-to-severely active Crohn's disease)
15. Guidelines Developed for Crohn Disease Management With Biomarkers
16. Clearance sought for Tremfya for Crohn's disease
17. MPR Weekly Dose Podcast #177
18. Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD
19. Darvadstrocel Misses as Treatment for Complex Perianal Fistulas in Crohn Disease
20. Long-Term Clinical Remission Observed With Mirikizumab in Crohn Disease Trial
21. Investigational Antifibrotic Therapy Fast Tracked for Fibrostenosing Crohn Disease
22. Adalimumab-adbm Injection, an Interchangeable Biosimilar to Humira, Now Available
23. MPR Weekly Dose #174
24. Vedolizumab SC Under Review for Maintenance Therapy in Crohn Disease
25. Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results
26. Findings on Ulcerative Colitis Discussed by Investigators at University of Chicago Medicine (Upadacitinib Is Effective and Safe In Both Ulcerative Colitis and Crohn's Disease: Prospective Real-world Experience)
27. Natalizumab Biosimilar Approved By FDA for Multiple Sclerosis
28. Investigators at Janssen Research & Development LLC Report Findings in Crohn's Disease (Model-based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-natural Killer Group 2 Member D Monoclonal Antibody, In Moderately To Severely ...)
29. Rinvoq Approved for Moderately to Severely Active Crohn Disease
30. Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
31. FDA Approves Biosimilar Hyrimoz High-Concentration Formulation
32. U.S. FDA OKs Subcutaneous Administration of Takedas ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohns Disease
33. Reports from University of Ulsan Describe Recent Advances in Crohn's Disease (P762 Population Pharmacokinetic Model of Intravenous Infliximab in Korean Patients with Crohn's Disease)
34. New Ulcerative Colitis Research Has Been Reported by a Researcher at Ankara University School of Medicine (P401 Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis)
35. Amjevita, a Biosimilar to Humira, Now Available
36. Ustekinumab Concentrations Linked to Crohn Disease Radiologic, Biomarker Outcomes
37. Guideline Addresses Anorectal Abscess; Anal, Rectovaginal Fistulas
38. AbbVie Seeks Crohn Disease Indication for Upadacitinib
39. Natalizumab Biosimilar to Get FDA Review for MS, Crohn Disease Indications
40. FDA to Review Biosimilar Hyrimoz High Concentration Formulation
41. June 2022: Notable Drug Approvals
42. FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
43. Skyrizi Approved for Moderately to Severely Active Crohn Disease
44. Upadacitinib Meets Endpoints in Crohn Disease Maintenance Trial
45. New Biologics Findings Has Been Reported by Investigators at University of Washington (Safety and Efficacy of Tofacitinib In Combination With Biologic Therapy for Refractory Crohn's Disease)
46. 'successive Supply Of Drugs Used In Drug Programs: - B55 - Treatment Of Patients With Ulcerative Colitis - B32 - Treatment Of Lesniowski - Crohn~s Disease'
47. Drug Delivery And Placebo (...) 'to Evaluate The Effectiveness Of Topical Budesonide Treatment In Children With Crohn~s Disease Located In The Esophagus And|Or Stomach And|Or Duodenum.'
48. FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
49. Pregnancy, Crohn's disease and Azathioprine: a case study and literature review
50. Medicinal Products - Drug Programs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.